Amidst the backdrop of rising oil prices and geopolitical tensions, Asian markets have experienced a wave of volatility, with technology stocks particularly under pressure due to concerns over AI investment and financing. In such an environment, identifying stocks that are estimated to be trading below their intrinsic value can offer potential opportunities for investors looking to capitalize on market inefficiencies.
| Name | Current Price | Fair Value (Est) | Discount (Est) |
| Zhejiang Hisun Pharmaceutical (SHSE:600267) | CN¥13.40 | CN¥26.30 | 49% |
| Xiamen King Long Motor Group (SHSE:600686) | CN¥9.37 | CN¥18.52 | 49.4% |
| Wus Printed Circuit (Kunshan) (SZSE:002463) | CN¥104.57 | CN¥206.72 | 49.4% |
| Shizuki Electric (TSE:6994) | ¥1192.00 | ¥2356.40 | 49.4% |
| P&H Tech (KOSDAQ:A239890) | ₩3120.00 | ₩6201.00 | 49.7% |
| PAL GROUP Holdings (TSE:2726) | ¥1467.00 | ¥2902.59 | 49.5% |
| Nissui (TSE:1332) | ¥1084.00 | ¥2163.05 | 49.9% |
| Morinaga Milk Industry (TSE:2264) | ¥1077.00 | ¥2134.38 | 49.5% |
| Kumagai GumiLtd (TSE:1861) | ¥1235.00 | ¥2437.97 | 49.3% |
| KB Financial Group (KOSE:A105560) | ₩154000.00 | ₩304406.46 | 49.4% |
Here we highlight a subset of our preferred stocks from the screener.
Overview: Ingenic Semiconductor Co., Ltd. designs, develops, and sells system-on-a-chip (SoC) products for various electronic devices worldwide, with a market capitalization of approximately CN¥56.27 billion.
Operations: Ingenic Semiconductor generates revenue through the design, development, and sale of system-on-a-chip (SoC) products for a range of electronic devices on a global scale.
Estimated Discount To Fair Value: 38.5%
Ingenic Semiconductor is trading at 38.5% below its estimated fair value and significantly below its future cash flow value, indicating it may be undervalued based on cash flows. Recent earnings showed substantial growth, with net income reaching CN¥2.62 billion for the nine months ended September 30, 2026, up from CN¥255.74 million a year ago. Despite high share price volatility recently, the company's earnings and revenue are forecast to grow faster than the market average in China.
Overview: Shenzhen New Industries Biomedical Engineering Co., Ltd. focuses on the research, development, production, and sale of clinical laboratory instruments and in vitro diagnostic reagents for hospitals both in China and internationally, with a market cap of CN¥45.75 billion.
Operations: The company's revenue primarily comes from its in vitro diagnostic segment, which generated CN¥4.84 billion.
Estimated Discount To Fair Value: 40.8%
Shenzhen New Industries Biomedical Engineering is trading 40.8% below its estimated fair value and significantly under its future cash flow value, suggesting undervaluation based on cash flows. Recent earnings reports show net income of CNY 1,390.59 million for the nine months ended September 30, 2026, up from CNY 1,204.8 million a year ago. However, earnings and revenue growth forecasts are slower than China's market average despite current good relative value compared to peers.
Overview: Taiwan Semiconductor Manufacturing Company Limited, along with its subsidiaries, is involved in the manufacturing, packaging, testing, and selling of integrated circuits and other semiconductor devices across various global markets; it has a market cap of NT$62.89 trillion.
Operations: The company's revenue primarily comes from its Foundry segment, which generated NT$4.94 billion.
Estimated Discount To Fair Value: 10.4%
Taiwan Semiconductor Manufacturing is trading 10.4% below its fair value estimate, reflecting potential undervaluation based on cash flows. Recent earnings showed substantial growth, with net income rising to TWD 763.06 billion for Q3 2026 from TWD 452.30 billion a year ago. Despite slower expected profit growth compared to the Taiwan market, revenue forecasts remain robust, outpacing market averages. Strategic alliances and technological advancements further bolster its competitive positioning in the semiconductor industry.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com